U.S. stock market midday update: CRISPR Therap up 7.25%
I'm LongbridgeAI, I can summarize articles.CRISPR Therap rose 7.25%; ProKidney rose 25.16%, with a transaction volume of USD 1.075 billion; Calidi Biotherapeutics rose 232.87%, with a transaction volume of USD 561 million; Abbvie fell 0.12%, with a transaction volume of USD 331 million, and a market capitalization of USD 334.8 billion
U.S. Stock Market Midday Update
CRISPR Therap, up 7.25%, with increased trading volume. Based on recent important news:
- On July 8, Chan Zuckerberg Initiative and Innovative Genomics Institute announced funding for the progress of personalized CRISPR Therap. This news boosted market confidence, driving CRISPR Therap's stock price up 7.25%.
Top Stocks by Industry Trading Volume
ProKidney up 25.16%, with a trading volume of 1.075 billion. Based on recent important news:
-
On July 8, ProKidney announced positive results from its REGEN-007 trial, showing that Rilparencel significantly improved eGFR slope in chronic kidney disease patients, leading to a 25% increase in stock price.
-
On July 9, the FDA confirmed that it would consider accelerated approval if Phase 3 trial results are similar, with optimistic market sentiment driving the stock price further up.
-
On July 10, Citigroup raised ProKidney's target price from $6 to $9, further stimulating the stock price increase.
Calidi Biotherapeutics up 232.87%. Based on recent key news:
-
On July 8, Calidi Biotherapeutics announced its mention in an editorial by NetworkNewsWire, increasing market attention to its brand, resulting in a significant stock price surge.
-
Over the past 5 days, Calidi Biotherapeutics' stock price has cumulatively risen by 384.83%, showing strong investor confidence in its future development.
-
Recent trading volume reached $561 million, indicating a significant increase in market interest in the company.
Abbvie down 0.12%, with increased trading volume. Based on recent important news:
-
On July 9, analysts noted that Abbvie was not on the recommended list, despite a moderate buy rating, leading to pressure on the stock price.
-
On July 9, increased volatility in the innovative drug industry and turmoil in overseas markets affected investor confidence, causing Abbvie's stock price to decline.
-
On July 7, progress in CAR-T cell therapy in the field of autoimmune diseases failed to boost Abbvie's stock price.
Top Stocks by Industry Market Capitalization
Abbvie down 0.12%, with increased trading volume. Based on recent important news:
-
On July 9, analysts noted that Abbvie was not on the recommended buy list, despite its moderate buy rating, leading to insufficient market confidence and a decline in stock price.
-
On July 9, high volatility in the innovative drug industry and investor bias affected market sentiment, leading to stock price fluctuations On July 7th, the application prospects of CAR-T cell therapy in autoimmune diseases attracted market attention, but failed to boost Abbvie's stock price